MAPS has announced further developments in its Phase 3 study of MDMA-assisted therapy for the treatment of PTSD.
Psychedelic-assisted therapy company Better U has created a Military Liaison Officer position to help expand access for veterans.
Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...
The clinical trial, carried out by a wholly-owned subsidiary of Creso Pharma Limited, Halucenex Life Sciences Inc.,
The clinical trial will be testing the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD).
The Phase II clinical trial will test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD).
MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Vancouver-based Apex Labs has received approval for a Phase IIa clinical trial exploring psilocybin treatment for post-traumatic stress disorder (PTSD) in veterans.
